Evolus, Inc. provided earnings guidance for the full year 2022. For the period, the company expects sales at the top end of its guidance range of $143 to $150 million equating to a year-over-year growth rate of approximately 50%, which is roughly triple the projected toxin market growth rate.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13 USD | +0.50% | +2.77% | +23.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.27% | 810M | |
+42.09% | 739B | |
+32.34% | 598B | |
-5.91% | 353B | |
+17.45% | 318B | |
+3.50% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+5.98% | 164B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Provides Earnings Guidance for the Full Year 2022